Table 1. Patient characteristics.
| ER β (−) | ER β (+) | p value | |
|---|---|---|---|
| No. | 53 | 52 | |
| Follow duration | 39.5 ± 34.3 | 34.6 ± 23.9 | 0.404 |
| Age | 68.6 ± 10.8 | 68.6 ± 10.0 | 0.975 |
| Smoking | 7(13.2%) | 7(13.5%) | 0.969 |
| Bladder cancer history | 3(5.7%) | 8(15.4%) | 0.119 |
| Infiltrating tumor | 22(41.5%) | 9(17.3%) | 0.004 |
| LN positive | 2(3.8%) | 4(7.7%) | 0.414 |
| LVI | 27(50.9%) | 20(38.5%) | 0.144 |
| CIS | 16(30.2%) | 20(38.5%) | 0.452 |
| SCC diff. | 19(35.8%) | 18(34.6%) | 0.782 |
| TN | 17(32.1%) | 27(51.9%) | 0.060 |
| Multifocal tumor | 9(17.0%) | 9(17.3%) | 0.965 |
| High grade | 52(98.1%) | 52(100%) | 0.320 |
| Bladder recurrence | 9(17.0%) | 11(21.2%) | 0.653 |
| Local recurrence | 24(45.3%) | 14(26.9%) | 0.035 |
| Distant metastasis | 26(49.1%) | 12(23.1%) | 0.004 |
| Cancer specific mortality | 17(32.1%) | 6(11.5%) | 0.008 |
Abbreviation: TN = Tumor necrosis, CIS = Carcinoma in situ, LVI = Lymphovascular invasion, SCC diff = Squamous differentiation, LN = Lymph node.